Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deanna A Mele

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
European Journal of Immunology|April 7, 2011
Th17 differentiation is the default program for DPP2-deficient T-cell differentiationDeanna A Mele, James F Sampson, Brigitte T Huber
Current Medicinal Chemistry|June 29, 2019
The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer ImmunotherapyDaniel H O' Donovan, Yumeng Mao, Deanna A Mele
Molecular Immunology|June 17, 2008
Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1Pradeep Bista, Deanna A Mele, Diana Velez Baez, et al.
Cell Cycle (Georgetown, Tex.)|June 27, 2009
Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescenceDeanna A Mele, Pradeep Bista, Diana Velez Baez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 4, 2022
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapyAatman S Doshi, Susan Cantin, Laura B Prickett, et al.
The Journal of Experimental Medicine|October 9, 2013
BET bromodomain inhibition suppresses TH17-mediated pathologyDeanna A Mele, Andres Salmeron, Srimoyee Ghosh, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Targeting MYC dependence in cancer by inhibiting BET bromodomainsJennifer A Mertz, Andrew R Conery, Barbara M Bryant, et al.
Cell Death & Disease|January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activityDane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Oncoimmunology|September 18, 2018
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunitySophie Langdon, Adina Hughes, Molly A Taylor, et al.
Endocrinology|October 13, 2009
Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesityOlga V Danilova, Albert K Tai, Deanna A Mele, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
European Journal of Immunology|April 7, 2011
Th17 differentiation is the default program for DPP2-deficient T-cell differentiationDeanna A Mele, James F Sampson, Brigitte T Huber
Current Medicinal Chemistry|June 29, 2019
The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer ImmunotherapyDaniel H O' Donovan, Yumeng Mao, Deanna A Mele
Molecular Immunology|June 17, 2008
Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1Pradeep Bista, Deanna A Mele, Diana Velez Baez, et al.
Cell Cycle (Georgetown, Tex.)|June 27, 2009
Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescenceDeanna A Mele, Pradeep Bista, Diana Velez Baez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 4, 2022
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapyAatman S Doshi, Susan Cantin, Laura B Prickett, et al.
The Journal of Experimental Medicine|October 9, 2013
BET bromodomain inhibition suppresses TH17-mediated pathologyDeanna A Mele, Andres Salmeron, Srimoyee Ghosh, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Targeting MYC dependence in cancer by inhibiting BET bromodomainsJennifer A Mertz, Andrew R Conery, Barbara M Bryant, et al.
Cell Death & Disease|January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activityDane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Oncoimmunology|September 18, 2018
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunitySophie Langdon, Adina Hughes, Molly A Taylor, et al.
Endocrinology|October 13, 2009
Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesityOlga V Danilova, Albert K Tai, Deanna A Mele, et al.
Pageof 2